BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9160261)

  • 1. The new inhibitors of ribonucleotide reductase--comparison of some physico-chemical properties.
    Romanova D; Vachalkova A; Szekeres T; Elford HL; Novotny L
    J Pharm Biomed Anal; 1997 Apr; 15(7):951-6. PubMed ID: 9160261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron binding capacity of didox (3,4 dihydroxybenzohydroxamic acid) and amidox (3,4 dihydroxybenzamidoxime) two inhibitors of the enzyme ribonucleotide reductase.
    Fritzer-Szekeres M; Novotny L; Vachalkova A; Göbl R; Elford HL; Szekeres T
    Adv Exp Med Biol; 1998; 431():599-604. PubMed ID: 9598136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA-protective activity of new ribonucleotide reductase inhibitors.
    Rauko P; Romanova D; Miadokova E; Macakova K; Novotny L; Elford HL; Szekeres T
    Anticancer Res; 1997; 17(5A):3437-40. PubMed ID: 9413183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase.
    Fritzer-Szekeres M; Novotny L; Vachalkova A; Findenig G; Elford HL; Szekeres T
    Life Sci; 1997; 61(22):2231-7. PubMed ID: 9393942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells.
    Myette MS; Elford HL; Chitambar CR
    Cancer Lett; 1998 Jul; 129(2):199-204. PubMed ID: 9719462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotoxic properties of the newly synthesized antineoplastic agents amidox, didox and trimidox.
    Miadoková E; Macáková K; Podstavková S; Vlcek D
    Pharmazie; 1997 Jul; 52(7):540-4. PubMed ID: 9266591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox.
    Grusch M; Fritzer-Szekeres M; Fuhrmann G; Rosenberger G; Luxbacher C; Elford HL; Smid K; Peters GJ; Szekeres T; Krupitza G
    Exp Hematol; 2001 May; 29(5):623-32. PubMed ID: 11376876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin.
    Iyamu WE; Adunyah SE; Fasold H; Horiuchi K; Elford HL; Asakura T; Turner EA
    Am J Hematol; 2000 Apr; 63(4):176-83. PubMed ID: 10706760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.
    Mayhew CN; Phillips JD; Greenberg RN; Birch NJ; Elford HL; Gallicchio VS
    Stem Cells; 1999; 17(6):345-56. PubMed ID: 10606163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron binding capacity of trimidox (3,4,5-trihydroxybenzamidoxime), a new inhibitor of the enzyme ribonucleotide reductase.
    Szekeres T; Vielnascher E; Novotny L; Vachalkova A; Fritzer M; Findenig G; Göbl R; Elford HL; Goldenberg H
    Eur J Clin Chem Clin Biochem; 1995 Nov; 33(11):785-9. PubMed ID: 8620054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
    Tihan T; Elford HL; Cory JG
    Adv Enzyme Regul; 1991; 31():71-83. PubMed ID: 1877400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea.
    Mayhew CN; Mampuru LJ; Chendil D; Ahmed MM; Phillips JD; Greenberg RN; Elford HL; Gallicchio VS
    Antiviral Res; 2002 Nov; 56(2):167-81. PubMed ID: 12367722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
    Figul M; Söling A; Dong HJ; Chou TC; Rainov NG
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):41-6. PubMed ID: 12690517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The ribonucleotide reductase enzyme as a target for enzyme-directed chemotherapy effects of trimidox (3,4,5-trihydroxybenzohydroxamidoxim), a new inhibitor of ribonucleotide reductases].
    Findenig G; Vielnascher E; Göbl R; Fritzer-Szekeres M; Szekeres T
    Wien Klin Wochenschr; 1995; 107(22):694-7. PubMed ID: 8533431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amidox, an inhibitor of ribonucleotide reductase, potentiates the action of Ara-C in HL-60 human promyelocytic leukemia cells.
    Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Fritzer-Szekeres M; Szekeres T
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1541-4. PubMed ID: 15571294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.
    Szekeres T; Gharehbaghi K; Fritzer M; Woody M; Srivastava A; van't Riet B; Jayaram HN; Elford HL
    Cancer Chemother Pharmacol; 1994; 34(1):63-6. PubMed ID: 8174204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS).
    Mayhew C; Oakley O; Piper J; Hughes NK; Phillips J; Birch NJ; Elford HL; Gallicchio VS
    Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):1019-29. PubMed ID: 9449534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis-inducing cleavage of caspases by trimidox, an inhibitor of ribonucleotide reductase.
    Fritzer-Szekeres M; Luxbacher C; Horvath Z; Grusch M; Krupitza G; Elford HL; Szekeres T
    Adv Exp Med Biol; 2000; 486():125-30. PubMed ID: 11783468
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
    Mayhew CN; Sumpter R; Inayat M; Cibull M; Phillips JD; Elford HL; Gallicchio VS
    Antiviral Res; 2005 Jan; 65(1):13-22. PubMed ID: 15652967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells.
    Fritzer-Szekeres M; Salamon A; Grusch M; Horvath Z; Höchtl T; Steinbrugger R; Jäger W; Krupitza G; Elford HL; Szekeres T
    Biochem Pharmacol; 2002 Aug; 64(3):481-5. PubMed ID: 12147300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.